Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
grade A 17.4 1.46% 0.25
COLL closed up 1.46 percent on Wednesday, November 14, 2018, on 1.19 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical COLL trend table...

Date Alert Name Type % Chg
Nov 14 Calm After Storm Range Contraction 0.00%
Nov 14 NR7 Range Contraction 0.00%
Nov 14 Stochastic Reached Overbought Strength 0.00%
Nov 14 Overbought Stochastic Strength 0.00%
Nov 14 Up 3 Days in a Row Strength 0.00%
Nov 14 Upper Bollinger Band Touch Strength 0.00%
Nov 13 Crossed Above 20 DMA Bullish 1.46%
Nov 13 Crossed Above 50 DMA Bullish 1.46%
Nov 13 MACD Bullish Signal Line Cross Bullish 1.46%
Nov 12 50 DMA Resistance Bearish 9.78%

Older signals for COLL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Is COLL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.9
52 Week Low 13.7
Average Volume 435,951
200-Day Moving Average 21.1882
50-Day Moving Average 16.054
20-Day Moving Average 16.296
10-Day Moving Average 16.107
Average True Range 1.047
ADX 16.11
+DI 20.8285
-DI 19.5288
Chandelier Exit (Long, 3 ATRs ) 14.699
Chandelier Exit (Short, 3 ATRs ) 16.841
Upper Bollinger Band 17.4404
Lower Bollinger Band 15.1516
Percent B (%b) 0.98
BandWidth 14.045164
MACD Line -0.0025
MACD Signal Line -0.0951
MACD Histogram 0.0925
Fundamentals Value
Market Cap 514.46 Million
Num Shares 29.6 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -4.85
Price-to-Sales 40.60
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.30
Resistance 3 (R3) 18.25 17.90 18.15
Resistance 2 (R2) 17.90 17.67 17.93 18.10
Resistance 1 (R1) 17.65 17.53 17.78 17.70 18.05
Pivot Point 17.30 17.30 17.36 17.33 17.30
Support 1 (S1) 17.05 17.07 17.18 17.10 16.75
Support 2 (S2) 16.70 16.93 16.73 16.70
Support 3 (S3) 16.45 16.70 16.65
Support 4 (S4) 16.50